小剂量倍他乐克治疗晚期扩张性心肌病疗效及安全性观察

目的 :评价小剂量倍他乐克治疗晚期扩张性心肌病 (DCM )的疗效及安全性。方法 :2 0例晚期扩张性心肌病患者 ,经充分抗心衰治疗后 ,按入院顺序 ,随机分为A组 (倍他乐克治疗组 )和B组 (常规治疗组 ) ,比较各组治疗前后及两组间临床指标及生活质量改善情况。结果 :两组临床症状、生活质量均较入院时明显改善。A组左室射血分数(LVEF)、6分钟步行距离 (D)较B组提高 ;心率 (HR) ,心率、平均动脉压 (MBp)乘积较B组下降 ,差异有显著性 (P <0 .0 1) ;A组再住院率、住院日数较B组低 ,所有患者均能良好耐受倍他乐克 ,无心功能恶化。结论 :在充分使用血管紧张素转换酶抑制剂 (ACEI)、利尿剂和洋地黄的基础上 ,采用小剂量倍他乐克治疗晚期扩张性心肌病 ,疗效及安全性均肯定

Effect and Safety of Low - dose Metroprol in Treating Patients with Congestive Heart Failure Secondary to Dilated Cardiomyopathy

Objective:To investigate the effect and safety of low-dose metroprol in treating patients with congestive heart failure(CHF) secondary to dilated cardiomyopathy (DCM).Method:20 CHF patients caused by DCM,after basic treatment for CHF, were randomly divided into two groups: group A (metroprol therapy group) and group B (traditional therapy group). Cardia morphologic and functional parameters in the two groups were examined with echocardiography before and after the treatment.Results:The clinical symptoms and life quality were obviously improved in both groups. There were significant differences in left ventricular ejection fraction(LVEF) and walking distances(WD) of six minutes between the two groups. Heart rate(HR), HR(MBP of group A were significantly lower than those of group B,P<0.01; The rate of repeated hospitalization of group A was lower than that of group B. All patients have a good tolerance,the heart function did not get worse.Conclusion:On the basis of full treatment with cardiotonic,diuretic and vessel dilator, low-dose metroprol is safe and effective in treating DCM combined with congestive heart failure.